The Prognosis, Prediction and Monitoring Tests are based on the molecular detection of Circulating Tumor Cells (CTCs) as a measure of therapy efficacy and recurrence of cancer. The presence and molecular characteristics of CTCs are analyzed by quantification of RNA panels specific for each type of cancer.
Our CTC tests provide reliable information
to stop ineffective treatment early on, avoiding unnecessary side effects which are a heavy burden for the patient;
to choose an alternative, more effective therapy;
to detect cancer relapse earlier than any other currently available method, enabling earliest possible onset of treatment.